知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.022 秒)

    HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS
    21.
    发明申请
    HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS 审中-公开
    金属化合物的羟基苯甲酸盐

    公开(公告)号：US20140288132A1

    公开(公告)日：2014-09-25

    申请号：US14296635

    申请日：2014-06-05

    申请人： Targacept, Inc.

    发明人： Julio A. Munoz ,  John Genus ,  James R. Moore

    IPC分类号： C07D213/65

    CPC分类号： A61K31/4406 ,  A61K31/192 ,  A61K31/44 ,  A61K31/4412 ,  C07D213/38 ,  C07D213/65 ,  C07D213/73 ,  C07D213/75 ,  C07D401/12

    摘要： Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.

    摘要翻译： 通过向有需要的患者施用作为E-间断脒类化合物的羟基苯甲酸盐的组合物来治疗易患或患有病症和障碍的患者，例如中枢神经系统疾病。 E-间烟碱化合物的羟基苯甲酸盐的形成也可用于纯化E-间烟碱化合物，因为羟基苯甲酸盐倾向于结晶出来，留下杂质如Z-间苯ic啶化合物和双键已经迁移的化合物 解。 如果需要，羟基苯甲酸盐可以转化为游离碱（E-间烟碱化合物）或另一种药学上可接受的盐形式。

    EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT
    23.
    发明申请
    EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT 有权
    EXO-S-MECAMYLAMINE配方和用于治疗

    公开(公告)号：US20140194525A1

    公开(公告)日：2014-07-10

    申请号：US14205721

    申请日：2014-03-12

    申请人： Targacept, Inc.

    发明人： Douglas Shytle ,  Paul Sanberg ,  Mary Newman ,  Archie A. Silver

    IPC分类号： C07C211/38

    CPC分类号： A61K31/13 ,  A61K9/0019 ,  C07C211/38

    摘要： A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

    摘要翻译： 药物组合物包括治疗有效量的外-S-麦卡胺或其药学上可接受的盐，其基本上不含外消旋的美沙酮与药学上可接受的载体的组合。 优选地，该量为约0.5mg至约20mg。 医疗条件通过施用治疗有效量的基本上不含其外消旋麦角胺的外-S-美卡咪胺或其药学上可接受的盐来治疗，所述量足以改善医疗状况。 医疗条件包括但不限于物质成瘾（涉及尼古丁，可卡因，酒精，苯丙胺，阿片剂，其他精神兴奋剂及其组合），帮助戒烟，治疗与戒烟相关的体重增加，高血压，高血压危象，Tourette综合征 其他震颤，癌症（如小细胞肺癌），致动脉粥样化特征，神经精神障碍（如双相性精神障碍，抑郁症，焦虑障碍，精神分裂症，癫痫发作障碍，帕金森病和注意缺陷多动障碍），慢性疲劳综合征， 克罗恩病，自主神经反射异常和痉挛性肠道疾病。

    HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS
    25.
    发明申请
    HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS 失效
    金属化合物的羟基苯甲酸盐

    公开(公告)号：US20140039014A1

    公开(公告)日：2014-02-06

    申请号：US14044914

    申请日：2013-10-03

    申请人： Targacept, Inc.

    发明人： Julio A. Munoz ,  John Genus ,  James R. Moore

    IPC分类号： C07D213/65

    CPC分类号： A61K31/4406 ,  A61K31/192 ,  A61K31/44 ,  A61K31/4412 ,  C07D213/38 ,  C07D213/65 ,  C07D213/73 ,  C07D213/75 ,  C07D401/12

    摘要： Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine) or to another pharmaceutically acceptable salt form.

    摘要翻译： 通过向有需要的患者施用作为E-间烟碱型化合物的羟基苯甲酸盐的组合物来治疗易患或患有病症和障碍的患者，例如中枢神经系统疾病。 E-间烟碱化合物的羟基苯甲酸盐的形成也可用于纯化E-间烟碱化合物，因为羟基苯甲酸盐倾向于结晶出来，留下杂质如Z-间苯ic啶化合物和双键已经迁移的化合物 解。 如果需要，羟基苯甲酸盐可以转化为游离碱（E-间烟碱）或另一种药学上可接受的盐形式。

    NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE
    26.
    发明申请
    NOVEL POLYMORPH FORMS OF (2S)-(4E)-N-METHYL-5-[3-(5-ISOPROPOXYPYRIDIN)YL]-4-PENTEN-2-AMINE 审中-公开
    （2S） - （4E）-N-甲基-5- [3-（5-异丙氧基吡啶）YL] -4-丁烯-2-胺的新型多聚体形式

    公开(公告)号：US20130310425A1

    公开(公告)日：2013-11-21

    申请号：US13893408

    申请日：2013-05-14

    申请人： Targacept, Inc.

    发明人： Gary Maurice Dull ,  Julio A. Munoz

    IPC分类号： C07D213/65

    CPC分类号： C07D213/65

    摘要： Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.

    摘要翻译： （2S） - （4E）-N-甲基-5- [3-（5-异丙氧基吡啶）基] -4-戊烯-2-胺对羟基苯甲酸酯的多晶型形式及其制备方法，含有所述多晶型物 （s）和使用。 可将多晶型物施用于易患或患有诸如中枢神经系统疾病的病症和病症的患者，以治疗和/或预防这些病症。

    HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS
    27.
    发明申请
    HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS 审中-公开
    金属化合物的羟基苯甲酸盐

    公开(公告)号：US20150313883A1

    公开(公告)日：2015-11-05

    申请号：US14796535

    申请日：2015-07-10

    申请人： Targacept, Inc.

    发明人： Julio A. Munoz ,  John Genus ,  James R. Moore

    IPC分类号： A61K31/44 ,  A61K31/192

    CPC分类号： C07D401/12 ,  A61K31/4406 ,  A61K31/4412 ,  C07D213/38 ,  C07D213/65 ,  C07D213/73 ,  C07D213/75

    摘要： Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.

    摘要翻译： 通过向有需要的患者施用作为E-间断脒类化合物的羟基苯甲酸盐的组合物来治疗易患或患有病症和障碍的患者，例如中枢神经系统疾病。 E-间烟碱化合物的羟基苯甲酸盐的形成也可用于纯化E-间烟碱化合物，因为羟基苯甲酸盐倾向于结晶出来，留下杂质如Z-间苯ic啶化合物和双键已经迁移的化合物 解。 如果需要，羟基苯甲酸盐可以转化为游离碱（E-间烟碱化合物）或另一种药学上可接受的盐形式。

    Hydroxybenzoate salts of metanicotine compounds
    29.
    发明授权
    Hydroxybenzoate salts of metanicotine compounds 有权
    间苯ine啶化合物的羟基苯甲酸盐

    公开(公告)号：US09107915B2

    公开(公告)日：2015-08-18

    申请号：US14296635

    申请日：2014-06-05

    申请人： Targacept, Inc.

    发明人： Julio A. Munoz ,  John Genus ,  James R. Moore

    IPC分类号： A61K31/4412 ,  A61K31/4406 ,  C07D213/38 ,  C07D213/65 ,  C07D213/73 ,  C07D213/75 ,  C07D401/12

    CPC分类号： A61K31/4406 ,  A61K31/192 ,  A61K31/44 ,  A61K31/4412 ,  C07D213/38 ,  C07D213/65 ,  C07D213/73 ,  C07D213/75 ,  C07D401/12

    摘要： Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof compositions that are hydroxybenzoate salts of E-metanicotine-type compounds. The formation of hydroxybenzoate salts of the E-metanicotine compounds is also useful in purifying the E-metanicotine compounds, as the hydroxybenzoate salts tend to crystallize out, leaving impurities such as Z-metanicotine compounds, and compounds where the double bond has migrated, in solution. If desired, the hydroxybenzoate salts can be converted to either the free base (the E-metanicotine compound) or to another pharmaceutically acceptable salt form.

    摘要翻译： 通过向有需要的患者施用作为E-间断脒类化合物的羟基苯甲酸盐的组合物来治疗易患或患有病症和障碍的患者，例如中枢神经系统疾病。 E-间烟碱化合物的羟基苯甲酸盐的形成也可用于纯化E-间烟碱化合物，因为羟基苯甲酸盐倾向于结晶出来，留下杂质如Z-间苯ic啶化合物和双键已经迁移的化合物 解。 如果需要，羟基苯甲酸盐可以转化为游离碱（E-间烟碱化合物）或另一种药学上可接受的盐形式。